Citigroup
HAE icon

Citigroup’s Haemonetics HAE Stock Holding History

Citigroup’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-220,000
Closed -$17.6M – 6127
2025
Q4 		$17.6M Buy
+220,000
New +$14.8M 0.01% 1186

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's HAE Position: Q2 2026 in Review

Citigroup increased its Haemonetics (HAE) stake by 27% in Q2 2026, buying an estimated $4.38M and bringing the position to 320,037 shares worth $24M. The position accounts for 0.01% of the portfolio, ranked #1071.

Citigroup first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $45.6M in Q4 2025. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Citigroup held 320,037 shares of Haemonetics worth $24M as of Q2 2026.
  • Citigroup bought 68,115 Haemonetics shares in Q2 2026, an estimated $4.38M.
  • Haemonetics made up 0.01% of Citigroup's portfolio in Q2 2026, its #1071 holding.
  • Citigroup first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Haemonetics position peaked at $45.6M in Q4 2025.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.